Think about the chart that shows that shows, "people are outright underestimating blisibimod's true market potential for a moderate to severe SLE population. Furthermore, B-Mod is proving to be a superior drug to HGSI/GSKs benlysta; because, among other things, B-Mod has met several important secondary endpoints and delivers essential ancillary benefits (Significant improvement in proteinuria over 24 weeks with the 200-milligram weekly dose, 1.6-fold improvement in the time to severe flare compared to placebo, 85% of the SRI-8 response was derived from clinical improvement such as improvements in joint pain, rash and oral lesions, etc.), many of which are being initiated in studies for future indications under their respective benefit profiles."
There are the only candles and chart you need to worry about.
Do you see this getting back to last years high? If this is superior to benlysta-HGSI/GSK and given current MC and no further dilution can this get to $15-20 upon approval, given benlysta has sales and possibly further competition from other Lupus developers. Thanks